JARDIANCE

Peak

empagliflozin

NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Sodium-Glucose Transporter 2 Inhibitors

Pharmacologic Class:

Sodium-Glucose Cotransporter 2 Inhibitor

Clinical Trials (5)

NCT07047508N/ANot Yet Recruiting

Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

Started Jan 2028
3,000 enrolled
Heart FailurePreserved Ejection Fraction
NCT07044700N/ANot Yet Recruiting

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Started Jan 2028
5,000 enrolled
Heart Failure of Reduced Ejection Fraction (HFrEF)
NCT07074418Phase 4Not Yet Recruiting

Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

Started Apr 2026
34 enrolled
Chronic Kidney Diseases
NCT07107945Phase 3Recruiting

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Started Dec 2025
120 enrolled
Chronic Kidney Disease
NCT07133399Phase 1Completed

A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood

Started Sep 2025
32 enrolled
Healthy

Loss of Exclusivity

LOE Date
Dec 11, 2034
106 months away
Patent Expiry
Dec 11, 2034
Exclusivity Expiry
Dec 20, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
7713938
Apr 15, 2027
SubstanceProduct
7713938*PED
Oct 15, 2027
7579449
Aug 1, 2028
Substance
7579449*PED
Feb 1, 2029
8551957
Oct 14, 2029
U-1651